(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 November 2010 (18.11.2010)

(51) International Patent Classification:
A61K 35/74 (2006.01) A23L 1/29 (2006.01)
A23L 1/30 (2006.01) A61P 37/04 (2006.01)

(21) International Application Number:
PCT/EP2010/056391

(22) International Filing Date:
11 May 2010 (11.05.2010)

(25) Filing Language: English
(26) Publication Language: English

(30) Priority Data:
09159925.8 11 May 2009 (11.05.2009) EP
09159929.0 11 May 2009 (11.05.2009) EP

(71) Applicant (for all designated States except US):
NESTEC S.A. [CH/CH]; Avenue Nestle 55, CH-1800 Vevey (CH).

(72) Inventors:

(75) Inventors/Applicants (for US only): MERCENIER, Annick [BE/CH]; Ch. de Rente 10, CH-1030 Bussigny (CH), NUTTEN, Sophie [FR/CH]; Av. de l’Avant poste, 3, CH-1005 Lausanne (CH). PRIOUALT, Guenolee [FR/CH]; Av. de Bethusy 15, CH-1005 Lausanne (CH).

(74) Agent: MARQUARDT, Ulf; Avenue Nestle 55, CH-1800 Vevey (CH).


(54) Title: ORAL NUTRITIONAL SUPPLEMENT FOR CHILDREN COMPRISING PROBIOTICS

(57) Abstract: The present invention relates to the field of nutrition for children. In particular, the present invention relates to the field of oral supplements. One embodiment of the present invention relates to the field of oral supplements comprising probiotics and/or bioactive non-replicating probiotics, for example heat treated probiotics.
The present invention relates to the field of nutrition for children. In particular, the present invention relates to the field of oral supplements. One embodiment of the present invention relates to the field of oral supplements comprising probiotics and/or bioactive non-replicating probiotics, for example heat treated probiotics.

Children have special nutritional needs. These needs vary greatly with the age and the developmental status of the child. Childhood is commonly understood as the time period between the stages of birth and puberty.

Because of the development of a child a normal balanced nutrition may not always be sufficient to provide sufficient nutrients to support the development of the child.

Also children may suffer from reduced appetite, volume intolerance, constipation or diarrhea, for example, which either do not allow sufficient food intake or do not allow that the required nutrients are properly absorbed from the ingested food.

Specialized dietary supplements have been developed for such cases so that the special requirements of children can still be met under such unfavorable circumstances.

Typically, in cases of insufficient food intake the macronutrients in the supplement are processed to make them easier to absorb. It would however be desirable to also support the gut function, so that the digestive system works more effectively.
Such supplements are typically directed towards a particular type of nutritional support. For example, a supplement may provide an individual with additional calories for increased energy or with an increased calcium amount to support bone development.

In case the composition is used when recovering from a disorder or surgery, it would also be desirable if the composition had an anti-inflammatory effect.

Children are often in close contact with many other children and require hence a strong immune system. Yet, depending on the developmental status, their immune system may still be immature.

It would hence further be desirable to provide children not only with nutritional support but also with support for the immune system, with a natural composition that allows to decrease the degree of inflammation in case a child is ill or recovering from illness and/or with means that allow a better functioning of the gut.

Presently these needs are addressed by providing processed macronutrients that allow easy absorption and by anti-inflammatory and/or immune boosting food ingredients or medicaments.

Still, there is a need in the art for a nutritional supplement that allows to provide children with specialized nutrition according to their specific needs while decreasing inflammation, boosting the immune system and/or improve digestion. It would be preferred if this was achieved by using natural ingredients that are safe to administer without side effects and that are easy to incorporate into nutritional supplements using industrial processing.
The present inventors have addressed this need. It was hence
the objective of the present invention to improve the state of
the art and to provide an oral nutritional supplement to be
administered to children that satisfies the needs expressed
above.

The present inventors were surprised that they could achieve
this object by the subject matter of the independent claim.
The dependant claims further develop the idea of the present
invention.

Accordingly, the present inventors propose to provide specific
oral nutritional supplements to be administered to children
comprising probiotics.

Children are to be understood for the purpose of the present
invention as humans between 1 and 13 years old.

Probiotics were found to be able to provide their health
benefits in the framework of liquid oral nutritional
supplements.

As liquid oral nutritional supplements usually have a shelf
life that exceeds the shelf life of yoghurt drinks comprising
probiotics, probiotics were usually not added to such
nutritional supplements, because of uncertainties that the
viability of the probiotics can be ensured during an extended
shelf life.

The present inventors were now able to show that even non-
replicating probiotics can provide the health benefits of
probiotics and may even have improved benefits.

Hence one embodiment of the present invention is an oral
nutritional supplement to be administered to children having a
caloric density in the range of 0.9-1.6 kcal/ml, an osmolality in the range of 380-420 m\(\text{Osm/kg water}, and comprising a protein source accounting for about 10-13 % of the calories of the composition, a carbohydrate source accounting for about 43-55 % of the calories of the composition, a lipid source accounting for about 33-46 % of the calories of the composition and probiotic micro-organisms.

The oral nutritional supplements of the present invention are preferably liquid oral nutritional supplements.

In one embodiment, such liquid oral nutritional supplements may be administered as enteral nutrition via tube feeding.

For example, the oral nutritional supplement may have a caloric density in the range of 0.9-1.1 kcal/ml, an osmolality in the range of 380-420 m\(\text{Osm/kg water}, and a protein source accounting for about 11-13 % of the calories of the composition, a carbohydrate source accounting for about 53-55 % of the calories of the composition, and a lipid source accounting for about 33-34 % of the calories of the composition.

Such a composition may contain Water, Sugar, Maltodextrin, Sodium Caseinate (Milk), High Oleic Sunflower Oil, Soybean Oil, Medium-Chain Triglycerides, Whey Protein Concentrate, Calcium Caseinate, for example.

Such a composition is well balanced and supports a healthy growth. It may be administered to children with special health needs, to children suffering from a Failure to Thrive, Gluten Intolerance, Inadequate Oral Intake, malnutrition, Lactose Intolerance, and/or an Reduced Appetite. It may also be administered before or after surgery.
The oral nutritional supplement may also have a caloric density in the range of 1.4-1.5 kcal/ml, an osmolality in the range of 380-400 m\(\text{osm/kg water}\), and a protein source accounting for about 11-12% of the calories of the composition, a carbohydrate source accounting for about 43-45% of the calories of the composition, and a lipid source accounting for about 44-46% of the calories of the composition.

Such a composition may contain Water, Sugar, Maltodextrin, Sodium Caseinate (Milk), High Oleic Sunflower Oil, Soybean Oil, Medium-Chain Triglycerides, Whey Protein Concentrate, Calcium Caseinate, for example.

Such a composition is well balanced and supports a healthy growth. It may be to be administered to children with special health needs, to children suffering from a Failure to Thrive, Gluten Intolerance, Inadequate Oral Intake, malnutrition, constipation, diarrhea, pediatric fluid restrictions, Lactose Intolerance, unintended weight loss and/or an Reduced Appetite. It may also be to be administered before or after surgery, in particular oral surgery.

The oral nutritional supplements of the present invention may additionally contain fiber. The fiber content may at least be in part soluble fibers. Preferred is a combination of soluble and insoluble fiber. The fibers may comprise soy fiber.

Also the fatty acid composition may be adjusted to a child's needs. Anti-inflammatory fatty acids may be used. For example, the oral nutritional supplement of the present invention may comprise a lipid source with a n6 : n3 fatty acid ratio in the range of 6:1 to 8:1.
The MCT (medium chain triglyceride) : LCT (long chain triglyceride) ratio may be in the range of 12:88 to 8:92.

The oral nutritional supplement of the present invention may comprise about 70-73% free water. Free water is essential to meet minimum fluid requirements. Typically, children with insufficient nutrient intake often also do not drink enough.

The oral nutritional supplement in accordance with the present invention may comprise a protein source selected from sodium and calcium caseinates from milk, whey protein concentrate or combinations thereof. The protein source may be adjusted to a child's needs. Typically, the nutritional supplement of the present invention may have an NPC:N ratio in the range of 190:1 to 210:1. The nonprotein kcal to nitrogen ratio (NPC:N) is calculated by calculating the grams of nitrogen supplied per day (1 g N = 6.25g protein) and by dividing the total nonprotein kcal by grams of nitrogen.

Typically, nutritional supplements with a NPC:N Ratio in the range of 80:1 is used for the most severely stressed patients, a NPC:N Ratio in the range of 100:1 is used for severely stressed patients and a NPC:N Ratio in the range of 150:1 is used for unstressed patients. Children generally do not require protein enriched foods, so that the NPC:N ratio is preferably high.

The oral nutritional supplement may comprise in part or only non-replicating probiotic micro-organisms.

The inventors were surprised to see that, e.g., in terms of an immune boosting effect and/or in terms of an anti-inflammatory effect non-replicating probiotic microorganisms may even be more effective than replicating probiotic microorganisms.
This is surprising since probiotics are often defined as "live micro-organisms that when administered in adequate amounts confer health benefits to the host" (FAO/WHO Guidelines). The vast majority of published literature deals with live probiotics. In addition, several studies investigated the health benefits delivered by non-replicating bacteria and most of them indicated that inactivation of probiotics, e.g. by heat treatment, leads to a loss of their purported health benefit (Rachmilewitz, D., et al., 2004, Gastroenterology 126:520-528; Castagliuolo, et al., 2005, FEMS Immunol. Med. Microbiol. 43:197-204; Gill, H. S. and K. J. Rutherford, 2001, Br.J.Nutr. 86:285-289; Kaila, M., et al., 1995, Arch. Dis. Child 72:51-53.). Some studies showed that killed probiotics may retain some health effects (Rachmilewitz, D., et al., 2004, Gastroenterology 126:520-528; Gill, H. S. and K. J. Rutherford, 2001, Br.J.Nutr. 86:285-289), but clearly, living probiotics were regarded in the art so far as more performing.

The oral nutritional supplement according to the present invention may comprise probiotic micro-organisms in any effective amount, for example in an amount corresponding to about $10^6$ to $10^{12}$ cfu/g dry weight.

The probiotic micro-organisms may be non-replicating probiotic micro-organisms.

"Non-replicating" probiotic micro-organisms include probiotic bacteria which have been heat treated. This includes micro-organisms that are inactivated, dead, non-viable and/or present as fragments such as DNA, metabolites, cytoplasmic compounds, and/or cell wall materials.

"Non-replicating" means that no viable cells and/or colony forming units can be detected by classical plating methods.
Such classical plating methods are summarized in the microbiology book: James Monroe Jay, Martin J. Loessner, David A. Golden. 2005. Modern food microbiology. 7th edition, Springer Science, New York, N.Y. 790 p. Typically, the absence of viable cells can be shown as follows: no visible colony on agar plates or no increasing turbidity in liquid growth medium after inoculation with different concentrations of bacterial preparations ('non replicating' samples) and incubation under appropriate conditions (aerobic and/or anaerobic atmosphere for at least 24h).

Probiotics are defined for the purpose of the present invention as "Microbial cell preparations or components of microbial cells with a beneficial effect on the health or well-being of the host." (Salminen s, Ouwehand A. Benno y. et al "Probiotics: how should they be defined" Trends Food Sci. Technol. 1999:10 107-10).

The possibility to use non-replicating probiotic microorganisms offers several advantages. In severely immuno-compromised children, the use of live probiotics may be limited in exceptional cases due to a potential risk to develop bacteremia. Non-replicating probiotics may be used without any problem.

Additionally, the provision of non-replicating probiotic micro-organisms allows the hot reconstitution while retaining health benefit.

The compositions of the present invention comprise probiotic micro-organisms and/or non-replicating probiotic micro-organisms in an amount sufficient to at least partially produce a health benefit. An amount adequate to accomplish this is defined as "a therapeutically effective dose". Amounts effective for this purpose will depend on a number of factors.
known to those of skill in the art such as the weight and
general health state of the child, and on the effect of the
food matrix.

In prophylactic applications, compositions according to the
invention are administered to a consumer susceptible to or
otherwise at risk of a disorder in an amount that is
sufficient to at least partially reduce the risk of developing
that disorder. Such an amount is defined to be "a prophylactic
effective dose". Again, the precise amounts depend on a number
of factors such as the child's state of health and weight, and
on the effect of the food matrix.

Those skilled in the art will be able to adjust the
therapeutically effective dose and/or the prophylactic
effective dose appropriately.

In general the composition of the present invention contains
probiotic micro-organisms and/or non-replicating probiotic
micro-organisms in a therapeutically effective dose and/or in
a prophylactic effective dose.

Typically, the therapeutically effective dose and/or the
prophylactic effective dose is in the range of about 0.005 mg
- 1000 mg probiotic micro-organisms and/or non-replicating,
probiotic micro-organisms per daily dose.

In terms of numerical amounts, the "short-time high
temperature" treated non-replicating micro-organisms may be
present in the composition in an amount corresponding to
between $10^4$ and $10^{12}$ equivalent cfu/g of the dry composition.
Obviously, non-replicating micro-organisms do not form
colonies, consequently, this term is to be understood as the
amount of non replicating micro-organisms that is obtained
from $10^4$ and $10^{12}$ cfu/g replicating bacteria. This includes
micro-organisms that are inactivated, non-viable or dead or present as fragments such as DNA or cell wall or cytoplasmic compounds. In other words, the quantity of micro-organisms which the composition contains is expressed in terms of the colony forming ability (cfu) of that quantity of micro-organisms as if all the micro-organisms were alive irrespective of whether they are, in fact, non replicating, such as inactivated or dead, fragmented or a mixture of any or all of these states.

Preferably the non-replicating micro-organisms are present in an amount equivalent to between $10^4$ to $10^9$ cfu/g of dry composition, even more preferably in an amount equivalent to between $10^5$ and $10^9$ cfu/g of dry composition.

The probiotics may be rendered non-replicating by any method that is known in the art.

The technologies available today to render probiotic strains non-replicating are usually heat-treatment, γ-irradiation, UV light or the use of chemical agents (formalin, paraformaldehyde).

It would be preferred to use a technique to render probiotics non-replicating that is relatively easy to apply under industrial circumstances in the food industry.

Most products on the market today that contain probiotics are heat treated during their production. It would hence be convenient, to be able to heat treat probiotics either together with the produced product or at least in a similar way, while the probiotics retain or improve their beneficial properties or even gain a new beneficial property for the consumer.
However, inactivation of probiotic micro-organisms by heat treatments is associated in the literature generally with at least partial loss of probiotic activity.

The present inventors have now surprisingly found, that rendering probiotic micro-organisms non-replicating, e.g., by heat treatment, does not result in the loss of probiotic health benefits, but – to the contrary – may enhance existing health benefits and even generate new health benefits.

Hence, one embodiment of the present invention is an oral nutritional supplement wherein the non-replicating probiotic micro-organisms were rendered non-replicating by a heat-treatment.

Such a heat treatment may be carried out at at least 71.5 °C for at least 1 second.

Long-term heat treatments or short-term heat treatments may be used.

In industrial scales today usually short term heat treatments, such as UHT-like heat treatments are preferred. This kind of heat treatment reduces bacterial loads, and reduces the processing time, thereby reducing the spoiling of nutrients.

The inventors demonstrate for the first time that probiotics micro-organisms, heat treated at high temperatures for short times exhibit anti-inflammatory immune profiles regardless of their initial properties. In particular either a new anti-inflammatory profile is developed or an existing anti-inflammatory profile is enhanced by this heat treatment.

It is therefore now possible to generate non replicating probiotic micro-organisms with anti-inflammatory immune
profiles by using specific heat treatment parameters that correspond to typical industrially applicable heat treatments, even if live counterparts are not anti-inflammatory strains.

Hence, for example, the heat treatment may be a high temperature treatment at about 71.5-150 °C for about 1-120 seconds. The high temperature treatment may be a high temperature/short time (HTST) treatment or a ultra-high temperature (UHT) treatment.

The probiotic micro-organisms may be subjected to a high temperature treatment at about 71.5-150 °C for a short term of about 1-120 seconds.

More preferred the micro-organisms may be subjected to a high temperature treatment at about 90 - 140 °C, for example 90°-120 °C, for a short term of about 1-30 seconds.

This high temperature treatment renders the micro-organisms at least in part non-replicating.

The high temperature treatment may be carried out at normal atmospheric pressure but may be also carried out under high pressure. Typical pressure ranges are from 1 to 50 bar, preferably from 1-10 bar, even more preferred from 2 to 5 bar. Obviously, it is preferred if the probiotics are heat treated in a medium that is either liquid or solid, when the heat is applied. An ideal pressure to be applied will therefore depend on the nature of the composition which the micro-organisms are provided in and on the temperature used.

The high temperature treatment may be carried out in the temperature range of about 71.5-150 °C, preferably of about 90-120 °C, even more preferred of about 120-140 °C.
The high temperature treatment may be carried out for a short term of about 1-120 seconds, preferably, of about 1-30 seconds, even more preferred for about 5-15 seconds.

This given time frame refers to the time the probiotic micro-organisms are subjected to the given temperature. Note, that depending on the nature and amount of the composition the micro-organisms are provided in and depending on the architecture of the heating apparatus used, the time of heat application may differ.

Typically, however, the composition of the present invention and/or the micro-organisms are treated by a high temperature short time (HTST) treatment, flash pasteurization or a ultra high temperature (UHT) treatment.

A UHT treatment is Ultra-high temperature processing or a ultra-heat treatment (both abbreviated UHT) involving the at least partial sterilization of a composition by heating it for a short time, around 1-10 seconds, at a temperature exceeding 135°C (275°F), which is the temperature required to kill bacterial spores in milk. For example, processing milk in this way using temperatures exceeding 135°C permits a decrease of bacterial load in the necessary holding time (to 2-5 s) enabling a continuous flow operation.

There are two main types of UHT systems: the direct and indirect systems. In the direct system, products are treated by steam injection or steam infusion, whereas in the indirect system, products are heat treated using plate heat exchanger, tubular heat exchanger or scraped surface heat exchanger. Combinations of UHT systems may be applied at any step or at multiple steps in the process of product preparation.
A HTST treatment is defined as follows (High Temperature/Short Time): Pasteurization method designed to achieve a 5-log reduction, killing 99,9999% of the number of viable microorganisms in milk. This is considered adequate for destroying almost all yeasts, molds and common spoilage bacteria and also ensure adequate destruction of common pathogenic heat resistant organisms. In the HTST process milk is heated to 71.7°C (161°F) for 15-20 seconds.

Flash pasteurization is a method of heat pasteurization of perishable beverages like fruit and vegetable juices, beer and dairy products. It is done prior to filling into containers in order to kill spoilage micro-organisms, to make the products safer and extend their shelf life. The liquid moves in controlled continuous flow while subjected to temperatures of 71.5°C (160°F) to 74°C (165°F) for about 15 to 30 seconds.

For the purpose of the present invention the term "short time high temperature treatment" shall include high-temperature short time (HTST) treatments, UHT treatments, and flash pasteurization, for example.

Since such a heat treatment provides non-replicating probiotics with an improved anti-inflammatory profile, the oral nutritional supplement of the present invention may be for use in the prevention or treatment of inflammatory disorders.

The inflammatory disorders that can be treated or prevented by the composition of the present invention are not particularly limited. For example, they may be selected from the group consisting of acute inflammations such as sepsis; burns; and chronic inflammation, such as inflammatory bowel disease, e.g., Crohn's disease, ulcerative colitis, pouchitis; necrotizing enterocolitis; skin inflammation, such as UV or
chemical-induced skin inflammation, eczema, reactive skin; irritable bowel syndrome; eye inflammation; allergy, asthma; and combinations thereof.

If long term heat treatments are used to render the probiotic micro-organisms non-replicating, such a heat treatment may be carried out in the temperature range of about 70-150 °C for about 3 minutes - 2 hours, preferably in the range of 80-140°C from 5 minutes - 40 minutes.

While the prior art generally teaches that bacteria rendered non-replicating by long-term heat-treatments are usually less efficient than live cells in terms of exerting their probiotic properties, the present inventors were able to demonstrate that heat-treated probiotics are superior in stimulating the immune system compared to their live counterparts.

The present invention relates also to an oral nutritional supplement comprising probiotic micro-organisms that were rendered non-replicating by a heat treatment at at least about 70 °C for at least about 3 minutes.

The immune boosting effects of non-replicating probiotics were confirmed by in vitro immunoprofiling. The in vitro model used uses cytokine profiling from human Peripheral Blood Mononuclear Cells (PBMCs) and is well accepted in the art as standard model for tests of immunomodulating compounds (Schultz et al., 2003, Journal of Dairy Research 70, 165-173; Taylor et al., 2006, Clinical and Experimental Allergy, 36, 1227-1235; Kekkonen et al., 2008, World Journal of Gastroenterology, 14, 1192-1203)

The in vitro PBMC assay has been used by several authors/research teams for example to classify probiotics according to their immune profile, i.e. their anti- or pro-
inflammatory characteristics (Kekkonen et al., 2008, World Journal of Gastroenterology, 14, 1192-1203). For example, this assay has been shown to allow prediction of an anti-inflammatory effect of probiotic candidates in mouse models of intestinal colitis (Foligne, B., et al., 2007, World J. Gastroenterol. 13:236-243). Moreover, this assay is regularly used as read-out in clinical trials and was shown to lead to results coherent with the clinical outcomes (Schultz et al., 2003, Journal of Dairy Research 70, 165-173; Taylor et al., 2006, Clinical and Experimental Allergy, 36, 1227-1235).

Allergic diseases have steadily increased over the past decades and they are currently considered as epidemics by WHO. In a general way, allergy is considered to result from an imbalance between the Th1 and Th2 responses of the immune system leading to a strong bias towards the production of Th2 mediators. Therefore, allergy can be mitigated, down-regulated or prevented by restoring an appropriate balance between the Th1 and Th2 arms of the immune system. This implies the necessity to reduce the Th2 responses or to enhance, at least transiently, the Th1 responses. The latter would be characteristic of an immune boost response, often accompanied by for example higher levels of IFNγ, TNF-α and IL-12. (Kekkonen et al., 2008, World Journal of Gastroenterology, 14, 1192-1203; Viljanen M. et al., 2005, Allergy, 60, 494-500)

The oral nutritional supplement of the present invention allows it hence to treat or prevent disorders that are related to a compromised immune defence.

Consequently, the disorders linked to a compromised immune defence that can be treated or prevented by the composition of the present invention are not particularly limited.
For example, they may be selected from the group consisting of infections, in particular bacterial, viral, fungal and/or parasite infections; phagocyte deficiencies; low to severe immunodepression levels such as those induced by stress or immunodepressive drugs, chemotherapy or radiotherapy; natural states of less immunocompetent immune systems such as those of the neonates; allergies; and combinations thereof.

The oral nutritional supplement described in the present invention allows it also to enhance a child's response to vaccines, in particular to oral vaccines.

Any amount of non-replicating micro-organisms will be effective. However, it is generally preferred, if at least 90 %, preferably, at least 95 %, more preferably at least 98 %, most preferably at least 99 %, ideally at least 99.9 %, most ideally all of the probiotics are non-replicating.

In one embodiment of the present invention all micro-organisms are non-replicating.

Consequently, in the oral nutritional supplement of the present invention at least 90 %, preferably, at least 95 %, more preferably at least 98 %, most preferably at least 99 %, ideally at least 99.9 %, most ideally all of the probiotics may be non-replicating.

All probiotic micro-organisms may be used for the purpose of the present invention.

For example, the probiotic micro-organisms may be selected from the group consisting of bifidobacteria, lactobacilli, propionibacteria, or combinations thereof, for example Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve,
Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli and/or mixtures thereof.

The oral nutritional supplement in accordance with the present invention may, for example comprise probiotic micro-organisms selected from the group consisting of Bifidobacterium longum NCC 3001, Bifidobacterium longum NCC 2705, Bifidobacterium breve NCC 2950, Bifidobacterium lactis NCC 2818, Lactobacillus johnsonii Lai, Lactobacillus paracasei NCC 2461, Lactobacillus rhamnosus NCC 4007, Lactobacillus reuteri DSM17983, Lactobacillus reuteri ATCC55730, Streptococcus thermophilus NCC 2019, Streptococcus thermophilus NCC 2059, Lactobacillus casei NCC 4006, Lactobacillus acidophilus NCC 3009, Lactobacillus casei ACA-DC 6002 (NCC 1825), Escherichia coli Nissle, Lactobacillus bulgaricus NCC 15, Lactococcus lactis NCC 2287, or combinations thereof.

All these strains were either deposited under the Budapest treaty and/or are commercially available.

The strains have been deposited under the Budapest treaty as follows:

Bifidobacterium longum NCC 3001: ATCC BAA-999
Bifidobacterium longum NCC 2705: CNCM 1-2618
Bifidobacterium breve NCC 2950: CNCM 1-3865
Bifidobacterium lactis NCC 2813; CNCM 1-344 6

Lactobacillus paracasei NCC 2461: CNCM 1-2116

Lactobacillus rhamnosus NCC 4007: CGMCC 1.3724

Streptococcus thermophilus NCC 2019: CNMC 1-1422

Streptococcus thermophilus NCC 2059: CNMC 1-4153

Lactococcus lactis NCC 2287: CNMC 1-4154

Lactobacillus casei NCC 4006: CNMC 1-1518

Lactobacillus casei NCC 1825: ACA-DC 6002

Lactobacillus acidophilus NCC 3009: ATCC 700396

Lactobacillus bulgaricus NCC 15: CNMC I-119S3

Lactobacillus johnsonii LaI CNCM 1-1225

Lactobacillus reuteri DSM17983 DSM17983

Lactobacillus reuteri ATCC55730 ATCC55730

Escherichia coli Nissle 1917: DSM 6601

Those skilled in the art will understand that they can freely combine all features of the present invention described herein, without departing from the scope of the invention as disclosed.

Further advantages and features of the present invention are apparent from the following Examples and Figures.
Figures 1 A and B show the enhancement of the anti-inflammatory immune profiles of probiotics treated with "short-time high temperatures".

Figure 2 shows non anti-inflammatory probiotic strains that become anti-inflammatory, i.e. that exhibit pronounced anti-inflammatory immune profiles in vitro after being treated with "short-time high temperatures".

Figures 3 A and B show probiotic strains in use in commercially available products that exhibit enhanced or new anti-inflammatory immune profiles in vitro after being treated with "short-time high temperatures".

Figures 4 A and B show dairy starter strains (i.e. LcI starter strains) that exhibit enhanced or new anti-inflammatory immune profiles in vitro upon heat treatment at high temperatures.

Figure 5 shows a non anti-inflammatory probiotic strain that exhibits anti-inflammatory immune profiles in vitro after being treated with HTST treatments.

Figure 6: Principal Component Analysis on PBMC data (IL-12p40, IFN-γ, TNF-α, IL-10) generated with probiotic and dairy starter strains in their live and heat treated (140°C for 15 second) forms. Each dot represents one strain either live or heat treated identified by its NCC number or name.

Figure 7 shows IL-12p40 / IL-10 ratios of live and heat treated (85°C, 20min) strains. Overall, heat treatment at 85°C for 20 min leads to an increase of IL-12p40 / IL-10 ratios as opposed to "short-time high temperature" treatments of the present invention (Figures 1, 2, 3, 4 and 5).
Figure 8 shows the enhancement of in vitro cytokine secretion from human PBMCs stimulated with heat treated bacteria.

Figure 9 shows the percentage of diarrhea intensity observed in OVA-sensitized mice challenged with saline (negative control), OVA-sensitized mice challenged with OVA (positive control) and OVA-sensitized mice challenged with OVA and treated with heat-treated or live Bifidobacterium breve NCC2950. Results are displayed as the percentage of diarrhea intensity (Mean ± SEM calculated from 4 independent experiments) with 100 % of diarrhea intensity corresponding to the symptoms developed in the positive control (sensitized and challenged by the allergen) group.

Example 1:

Methodology

Bacterial preparations:

The health benefits delivered by live probiotics on the host immune system are generally considered to be strain specific. Probiotics inducing high levels of IL-10 and/or inducing low levels of pro-inflammatory cytokines in vitro (PBMC assay) have been shown to be potent anti-inflammatory strains in vivo (Foligne, B., et al., 2007, World J.Gastroenterol. 13:236-243).

Several probiotic strains were used to investigate the anti-inflammatory properties of heat treated probiotics. These were Bifidobacterium longum NCC 3001, Bifidobacterium longum NCC 2705, Bifidobacterium breve NCC 2950, Bifidobacterium lactis NCC 2818, Lactobacillus paracasei NCC 2461, Lactobacillus rhamnosus NCC 4007, Lactobacillus casei NCC 4006, Lactobacillus acidophilus NCC 3009, Lactobacillus casei ACA-DC.
6002 (NCC 1825), and *Escherichia coli* Nissle. Several starter culture strains including some strains commercially used to produce Nestle LcI fermented products were also tested: *Streptococcus thermophilus* NCC 2019, *Streptococcus thermophilus* NCC 2059, *Lactobacillus bulgaricus* NCC 15 and *Lactococcus lactis* NCC 2287.

Bacterial cells were cultivated in conditions optimized for each strain in 5-15L bioreactors. All typical bacterial growth media are usable. Such media are known to those skilled in the art. When pH was adjusted to 5.5, 30% base solution (either NaOH or Ca(OH)$_2$) was added continuously. When adequate, anaerobic conditions were maintained by gassing headspace with CO$_2$. *E. coli* was cultivated under standard aerobic conditions.

Bacterial cells were collected by centrifugation (5,000 x g, 4°C) and re-suspended in phosphate buffer saline (PBS) in adequate volumes in order to reach a final concentration of around $10^9$ - $10^{10}$ cfu/ml. Part of the preparation was frozen at -80°C with 15% glycerol. Another part of the cells was heat treated by:

- **Ultra High Temperature**: 140°C for 15 sec; by indirect steam injection.

- **High Temperature Short Time (HTST)**: 74°C, 90°C and 120°C for 15 sec by indirect steam injection

- **Long Time Low Temperature** (85°C, 20 min) in water bath

Upon heat treatment, samples were kept frozen at -80°C until use.

*In vitro* immunoprofiling of bacterial preparations:
The immune profiles of live and heat treated bacterial preparations (i.e. the capacity to induce secretion of specific cytokines from human blood cells in vitro) were assessed. Human peripheral blood mononuclear cells (PBMCs) were isolated from blood filters. After separation by cell density gradient, mononuclear cells were collected and washed twice with Hank's balanced salt solution. Cells were then resuspended in Iscove's Modified Dulbecco's Medium (IMDM, Sigma) supplemented with 10% foetal calf serum (Bioconcept, Paris, france), 1% L-glutamine (Sigma), 1% penicillin/streptomycin (Sigma) and 0.1% gentamycin (Sigma). PBMCs (7x10^5 cells/well) were then incubated with live and heat treated bacteria (equivalent 7x10^6 cfu/well) in 48 well plates for 36h. The effects of live and heat treated bacteria were tested on PBMCs from 8 individual donors splitted into two separated experiments. After 36h incubation, culture plates were frozen and kept at -20°C until cytokine measurement. Cytokine profiling was performed in parallel (i.e. in the same experiment on the same batch of PBMCs) for live bacteria and their heat-treated counterparts.

Levels of cytokines (IFN-γ, IL-12p40, TNF-α and IL-IO) in cell culture supernatants after 36h incubation were determined by ELISA (R&D DuoSet Human IL-IO, BD OptEIA Human IL12p40, BD OptEIA Human TNFα, BD OptEIA Human IFN-γ) following manufacturer's instructions. IFN-γ, IL-12p40 and TNF-α are pro-inflammatory cytokines, whereas IL-IO is a potent anti-inflammatory mediator. Results are expressed as means (pg/ml) +/- SEM of 4 individual donors and are representative of two individual experiments performed with 4 donors each. The ratio IL-12p40 / IL-IO is calculated for each strain as a predictive value of in vivo anti-inflammatory effect (Foligne, B., et al., 2007, World J.Gastroenterol. 13:236-243).
Numerical cytokine values (pg/ml) determined by ELISA (see above) for each strain were transferred into BioNumerics v5.10 software (Applied Maths, Sint-Martens-Latem, Belgium). A Principal Component Analysis (PCA, dimensioning technique) was performed on this set of data. Subtraction of the averages over the characters and division by the variances over the characters were included in this analysis.

Results

Anti-inflammatory profiles generated by Ultra High Temperature (UHT) / High Temperature Short Time (HTST) -like treatments

The probiotic strains under investigation were submitted to a series of heat treatments (Ultra High Temperature (UHT), High Temperature Short Time (HTST) and 85°C for 20 min) and their immune profiles were compared to those of live cells in vitro. Live micro-organisms (probiotics and/or dairy starter cultures) induced different levels of cytokine production when incubated with human PBMC (Figures 1, 2, 3, 4 and 5). Heat treatment of these micro-organisms modified the levels of cytokines produced by PBMC in a temperature dependent manner. "Short-time high temperature" treatments (120°C or 140°C for 15'') generated non replicating bacteria with anti-inflammatory immune profiles (Figures 1, 2, 3 and 4). Indeed, UHT-like treated strains (140°C, 15 sec) induced less pro-inflammatory cytokines (TNF-α, IFN-γ, IL-12p40) while maintaining or inducing additional IL-10 production (compared to live counterparts). The resulting IL-12p40 / IL-10 ratios were lower for any UHT-like treated strains compared to live cells (Figures 1, 2, 3 and 4). This observation was also valid for bacteria treated by HTST-like treatments, i.e. submitted to 120°C for 15 sec (Figures 1, 2, 3 and 4), or 74°C and 90°C for 15 sec (Figure 5). Heat treatments (UHT-like or HTST-like
treatments) had a similar effect on in vitro immune profiles of probiotic strains (Figures 1, 2, 3 and 5) and dairy starter cultures (Figure 4). Principal Component Analysis on PBMC data generated with live and heat treated (140°C, 15”) probiotic and dairy starter strains revealed that live strains are spread all along the x axis, illustrating that strains exhibit very different immune profiles in vitro, from low (left side) to high (right side) inducers of pro-inflammatory cytokines. Heat treated strains cluster on the left side of the graph, showing that pro-inflammatory cytokines are much less induced by heat treated strains (Figure 6). By contrast, bacteria heat treated at 85°C for 20 min induced more pro-inflammatory cytokines and less IL-10 than live cells resulting in higher IL-12p40 / IL-10 ratios (Figure 7).

Anti-inflammatory profiles are enhanced or generated by UHT-like and HTST-like treatments.

UHT and HTST treated strains exhibit anti-inflammatory profiles regardless of their respective initial immune profiles (live cells). Probiotic strains known to be anti-inflammatory in vivo and exhibiting anti-inflammatory profiles in vitro (B. longum NCC 3001, B. longum NCC 2705, B. breve NCC 2950, B. lactis NCC 2818) were shown to exhibit enhanced anti-inflammatory profiles in vitro after "short-time high temperature" treatments. As shown in Figure 1, the IL-12p40 / IL-10 ratios of UHT-like treated Bifidobacterium strains were lower than those from the live counterparts, thus showing improved anti-inflammatory profiles of UHT-like treated samples. More strikingly, the generation of anti-inflammatory profiles by UHT-like and HTST-like treatments was also confirmed for non anti-inflammatory live strains. Both live L. rhamnosus NCC 4007 and L. paracasei NCC 2461 exhibit high IL-12p40 / IL-10 ratios in vitro (Figures 2 and 5). The two live
strains were shown to be not protective against TNBS-induced colitis in mice. The IL-12p40 / IL-10 ratios induced by *L. rhamnosus* NCC 4007 and *L. paracasei* NCC 2461 were dramatically reduced after "short-time high temperature" treatments (UHT or HTST) reaching levels as low as those obtained with *Bifidobacterium* strains. These low IL-12p40 / IL-10 ratios are due to low levels of IL-12p40 production combined with no change (*L. rhamnosus* NCC 4007) or a dramatic induction of IL-10 secretion (*L. paracasei* NCC 2461) (Figure 2).

As a consequence:

- Anti-inflammatory profiles of live micro-organisms can be enhanced by UHT-like and HTST-like heat treatments (for instance *B. longum* NCC 2705, *B. longum* NCC 3001, *B. breve* NCC 2950, *B. lactis* NCC 2818)

- Anti-inflammatory profiles can be generated from non anti-inflammatory live micro-organisms (for example *L. rhamnosus* NCC 4007, *L. paracasei* NCC 2461, dairy starters *S. thermophilus* NCC 2019) by UHT-like and HTST-like heat treatments.

- Anti-inflammatory profiles were also demonstrated for strains isolated from commercially available products (Figures 3 A & B) including a probiotic *E. coli* strain.

The impact of UHT/HTST-like treatments was similar for all tested probiotics and dairy starters, for example lactobacilli, bifidobacteria and streptococci.

UHT/HTST-like treatments were applied to several lactobacilli, bifidobacteria and streptococci exhibiting different *in vitro* immune profiles. All the strains induced less pro-inflammatory cytokines after UHT/HTST-like treatments than their live
counterparts (Figures 1, 2, 3, 4, 5 and 6) demonstrating that the effect of UHT/HTST-like treatments on the immune properties of the resulting non-replicating bacteria can be generalized to all probiotics, in particular to lactobacilli and bifidobacteria and specific E. coli strains and to all dairy starter cultures in particular to streptococci, lactobacilli and lactococci.

Example 2:

Methodology

**Bacterial preparations:**

Five probiotic strains were used to investigate the immune boosting properties of non-replicating probiotics: 3 bifidobacteria (*B. longum* NCC3001, *B. lactis* NCC2818, *B. breve* NCC2950) and 2 lactobacilli (*L. paracasei* NCC2461, *L. rhamnosus* NCC4007).

Bacterial cells were grown on MRS in batch fermentation at 37°C for 16-18h without pH control. Bacterial cells were spun down (5,000 x g, 4°C) and resuspended in phosphate buffer saline prior to be diluted in saline water in order to reach a final concentration of around 10E10 cfu/ml. *B. longum* NCC3001, *B. lactis* NCC2818, *L. paracasei* NCC2461, *L. rhamnosus* NCC4007 were heat treated at 85°C for 20 min in a water bath. *B. breve* NCC2950 was heat treated at 90°C for 30 minutes in a water bath. Heat treated bacterial suspensions were aliquoted and kept frozen at -80°C until use. Live bacteria were stored at -80°C in PBS-glycerol 15% until use.

*In vitro immunoprofiling of bacterial preparations*
The immune profiles of live and heat treated bacterial
preparations (i.e. the capacity to induce secretion of
specific cytokines from human blood cells in vitro) were
assessed. Human peripheral blood mononuclear cells (PBMCs)
were isolated from blood filters. After separation by cell
density gradient, mononuclear cells were collected and washed
twice with Hank's balanced salt solution. Cells were then
resuspended in Iscove's Modified Dulbecco's Medium (IMDM, Sigma) supplemented with 10% foetal calf serum (Bioconcept, Paris, France), 1% L-glutamine (Sigma), 1%
penicillin/streptomycin (Sigma) and 0.1% gentamycin (Sigma).
PBMCs (7x10^5 cells/well) were then incubated with live and heat
treated bacteria ( equivalent 7x10^6 cfu/well) in 48 well plates
for 36h. The effects of live and heat treated bacteria were
tested on PBMCs from 8 individual donors splitted into two
separate experiments. After 36h incubation, culture plates
were frozen and kept at -20°C until cytokine measurement.
Cytokine profiling was performed in parallel (i.e. in the same
experiment on the same batch of PBMCs) for live bacteria and
their heat-treated counterparts.

Levels of cytokines (IFN-γ, IL-12p40, TNF-α and IL-10) in cell
culture supernatants after 36h incubation were determined by
ELISA (R&D DuoSet Human IL-10, BD OptEIA Human IL12p40, BD
OptEIA Human TNF, BD OptEIA Human IFN-γ) following
manufacturer's instructions. IFN-γ, IL-12p40 and TNF-α are pro-
inflammatory cytokines, whereas IL-10 is a potent anti-
inflammatory mediator. Results are expressed as means (pg/ml)
+/− SEM of 4 individual donors and are representative of two
individual experiments performed with 4 donors each.

In vivo effect of live and heat treated Bifidobacterium breve
NCC2950 in prevention of allergic diarrhea
A mouse model of allergic diarrhea was used to test the Th1 promoting effect of *B. breve* NCC2950 (Brandt E. B et al. JCI 2003; 112(11): 1666-1667). Following sensitization (2 intraperitoneal injections of Ovalbumin (OVA) and aluminium potassium sulphate at an interval of 14 days; days 0 and 14) male Balb/c mice were orally challenged with OVA for 6 times (days 27, 29, 32, 34, 36, 39) resulting in transient clinical symptoms (diarrhea) and changes of immune parameters (plasma concentration of total IgE, OVA specific IgE, mouse mast cell protease 1, i.e. MMCP-I). *Bifidobacterium breve* NCC2950 live or heat treated at 90°C for 30min, was administered by gavage 4 days prior to OVA sensitization (days -3, -2, -1, 0 and days 11, 12, 13 and 14) and during the challenge period (days 23 to 39). A daily bacterial dose of around 10^9 colony forming units (cfu) or equivalent cfu/mouse was used.

**Results**

Induction of secretion of 'pro-inflammatory' cytokines after heat treatment

The ability of heat treated bacterial strains to stimulate cytokine secretion by human peripheral blood mononuclear cells (PBMCs) was assessed *in vitro*. The immune profiles based on four cytokines upon stimulation of PBMCs by heat treated bacteria were compared to that induced by live bacterial cells in the same *in vitro* assay.

The heat treated preparations were plated and assessed for the absence of any viable counts. Heat treated bacterial preparations did not produce colonies after plating.

Live probiotics induced different and strain dependent levels of cytokine production when incubated with human PBMCs (Figure 8). Heat treatment of probiotics modified the levels of
cytokines produced by PBMCs as compared to their live counterparts. Heat treated bacteria induced more pro-inflammatory cytokines (TNF-α, IFN-γ, IL-12p40) than their live counterparts do. By contrast heat treated bacteria induced similar or lower amounts of IL-10 compared to live cells (Figure 8). These data show that heat treated bacteria are more able to stimulate the immune system than their live counterparts and therefore are more able to boost weakened immune defences. In other words the in vitro data illustrate an enhanced immune boost effect of bacterial strains after heat treatment.

In order to illustrate the enhanced effect of heat-treated *B. breve* NCC2950 (compared to live cells) on the immune system, both live and heat treated *B. breve* NCC2950 (strain A) were tested in an animal model of allergic diarrhea.

As compared to the positive control group, the intensity of diarrhea was significantly and consistently decreased after treatment with heat treated *B. breve* NCC2950 (41.1 % ± 4.8) whereas the intensity of diarrhea was lowered by only 20 ± 28.3 % after treatment with live *B. breve* NCC2950. These results demonstrate that heat-treated *B. breve* NCC2950 exhibits an enhanced protective effect against allergic diarrhea than its live counterpart (Figure 9).

As a consequence, the ability of probiotics to enhance the immune defences was shown to be improved after heat treatment.

Examples 3-5:

The following compositions may be prepared:
Water, Sugar, Maltodextrin, Sodium Caseinate (Milk), High Oleic Sunflower Oil, Soybean Oil, Medium-Chain Triglycerides, Whey Protein Concentrate, Calcium Caseinate (A)

Water, Maltodextrin, Soybean Oil, Sodium Caseinate (From Milk), Sugar, High Oleic Sunflower Oil, Whey Protein Concentrate, Partially Hydrolyzed Guar Gum, Medium-Chain Triglycerides, Calcium Caseinate (C)

<table>
<thead>
<tr>
<th>Component</th>
<th>Formulation A</th>
<th>Formulation B</th>
<th>Formulation C</th>
</tr>
</thead>
<tbody>
<tr>
<td>kcal/mL</td>
<td>1.0</td>
<td>1.5</td>
<td>1.5</td>
</tr>
<tr>
<td>Caloric Distribution (% of kcal)</td>
<td>Protein: 12% Carbohydrate: 54% Fat: 34%</td>
<td>Protein: 11% Carbohydrate: 44% Fat: 45%</td>
<td>Protein: 11% Carbohydrate: 44% Fat: 45%</td>
</tr>
<tr>
<td>Protein Source</td>
<td>sodium and calcium caseinates (milk), whey protein concentrate</td>
<td>sodium and calcium caseinates (milk), whey protein concentrate</td>
<td>sodium and calcium caseinates (milk), whey protein concentrate</td>
</tr>
<tr>
<td>NPC:N Ratio</td>
<td>199:1</td>
<td>199:1</td>
<td>199:1</td>
</tr>
<tr>
<td>MCT:LCT Ratio</td>
<td>10:90</td>
<td>10:90</td>
<td>10:90</td>
</tr>
<tr>
<td>n6:n3 Ratio</td>
<td>6.9:1</td>
<td>6.9:1</td>
<td>6.9:1</td>
</tr>
<tr>
<td>Osmolality (mOsm/kg water)</td>
<td>390</td>
<td>405</td>
<td>405</td>
</tr>
<tr>
<td>Free Water</td>
<td>72 %</td>
<td>71 %</td>
<td>71 %</td>
</tr>
<tr>
<td>Fiber Content (soluble fiber, soy fiber):</td>
<td></td>
<td></td>
<td>9 g/L</td>
</tr>
<tr>
<td>Probiotics</td>
<td>$10^3$ cfu Lactobacillus johnsonii Lal</td>
<td>$10^7$ cfu heat treated (75°C, 20 min) Bifidobacterium longum NCC 3001</td>
<td>$10^3$ cfu UHT treated Lactobacillus johnsonii Lal</td>
</tr>
<tr>
<td>0-1</td>
<td>Form PCT/RO/134 (SAFE) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)</td>
<td>PCT Online Filing Version 3.5.000.204 MT/FOP 20020701/0.20.5.9</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>-----------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>0-2</td>
<td>International Application No.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-3</td>
<td>Applicant's or agent's file reference</td>
<td>NO 10855-WO</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-1</td>
<td>page</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>1-2</td>
<td>line</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>1-3</td>
<td>Identification of deposit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-3-1</td>
<td>Name of depositary institution</td>
<td>CNCM Collection nationale de cultures de micro-organismes</td>
<td></td>
</tr>
<tr>
<td>1-3-2</td>
<td>Address of depositary institution</td>
<td>Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France</td>
<td></td>
</tr>
<tr>
<td>1-3-3</td>
<td>Date of deposit</td>
<td>02 July 1992 (02.07.1992)</td>
<td></td>
</tr>
<tr>
<td>1-3-4</td>
<td>Accession Number</td>
<td>CNCM I-1225</td>
<td></td>
</tr>
<tr>
<td>1-5</td>
<td>Designated States for Which Indications are Made</td>
<td>all designations</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-1</td>
<td>page</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>2-2</td>
<td>line</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>2-3</td>
<td>Identification of deposit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-3-1</td>
<td>Name of depositary institution</td>
<td>CNCM Collection nationale de cultures de micro-organismes</td>
<td></td>
</tr>
<tr>
<td>2-3-2</td>
<td>Address of depositary institution</td>
<td>Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France</td>
<td></td>
</tr>
<tr>
<td>2-3-3</td>
<td>Date of deposit</td>
<td>02 March 2001 (02.03.2001)</td>
<td></td>
</tr>
<tr>
<td>2-3-4</td>
<td>Accession Number</td>
<td>CNCM I-2618</td>
<td></td>
</tr>
<tr>
<td>2-5</td>
<td>Designated States for Which Indications are Made</td>
<td>all designations</td>
<td></td>
</tr>
</tbody>
</table>
The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:

<table>
<thead>
<tr>
<th>3</th>
<th>page</th>
<th>18</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>line</td>
<td>29</td>
</tr>
</tbody>
</table>

**3-3 Identification of deposit**

- **Name of depositary institution**: CNCM Collection nationale de cultures de micro-organismes
- **Address of depositary institution**: Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France
- **Date of deposit**: 10 January 2008 (10.01.2008)
- **Accession Number**: CNCM I-3865

**3-5 Designated States for Which Indications are Made**: all designations

---

The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:

<table>
<thead>
<tr>
<th>4</th>
<th>page</th>
<th>19</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>line</td>
<td>1</td>
</tr>
</tbody>
</table>

**4-3 Identification of deposit**

- **Name of depositary institution**: CNCM Collection nationale de cultures de micro-organismes
- **Address of depositary institution**: Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France
- **Date of deposit**: 09 September 2005 (09.09.2005)
- **Accession Number**: CNCM I-3446

**4-5 Designated States for Which Indications are Made**: all designations

---

The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:

<table>
<thead>
<tr>
<th>5</th>
<th>page</th>
<th>19</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>line</td>
<td>2</td>
</tr>
</tbody>
</table>

**5-3 Identification of deposit**

- **Name of depositary institution**: CNCM Collection nationale de cultures de micro-organismes
- **Address of depositary institution**: Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France
- **Date of deposit**: 12 February 1999 (12.02.1999)
- **Accession Number**: CNCM I-2116

**5-5 Designated States for Which Indications are Made**: all designations
<table>
<thead>
<tr>
<th></th>
<th>The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-1</td>
<td>page</td>
<td>19</td>
</tr>
<tr>
<td>6-2</td>
<td>line</td>
<td>3</td>
</tr>
<tr>
<td>6-3</td>
<td>Identification of deposit</td>
<td></td>
</tr>
<tr>
<td>6-3-1</td>
<td>Name of depositary institution</td>
<td></td>
</tr>
<tr>
<td>6-3-2</td>
<td>Address of depositary institution</td>
<td></td>
</tr>
<tr>
<td>6-3-3</td>
<td>Date of deposit</td>
<td></td>
</tr>
<tr>
<td>6-3-4</td>
<td>Accession Number</td>
<td></td>
</tr>
<tr>
<td>6-5</td>
<td>Designated States for Which Indications are Made</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7-1</td>
<td>page</td>
<td>19</td>
</tr>
<tr>
<td>7-2</td>
<td>line</td>
<td>4</td>
</tr>
<tr>
<td>7-3</td>
<td>Identification of deposit</td>
<td></td>
</tr>
<tr>
<td>7-3-1</td>
<td>Name of depositary institution</td>
<td></td>
</tr>
<tr>
<td>7-3-2</td>
<td>Address of depositary institution</td>
<td></td>
</tr>
<tr>
<td>7-3-3</td>
<td>Date of deposit</td>
<td></td>
</tr>
<tr>
<td>7-3-4</td>
<td>Accession Number</td>
<td></td>
</tr>
<tr>
<td>7-5</td>
<td>Designated States for Which Indications are Made</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8-1</td>
<td>page</td>
<td>19</td>
</tr>
<tr>
<td>8-2</td>
<td>line</td>
<td>5</td>
</tr>
<tr>
<td>8-3</td>
<td>Identification of deposit</td>
<td></td>
</tr>
<tr>
<td>8-3-1</td>
<td>Name of depositary institution</td>
<td></td>
</tr>
<tr>
<td>8-3-2</td>
<td>Address of depositary institution</td>
<td></td>
</tr>
<tr>
<td>8-3-3</td>
<td>Date of deposit</td>
<td></td>
</tr>
<tr>
<td>8-3-4</td>
<td>Accession Number</td>
<td></td>
</tr>
<tr>
<td>8-5</td>
<td>Designated States for Which Indications are Made</td>
<td></td>
</tr>
</tbody>
</table>
The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:

<table>
<thead>
<tr>
<th>Page</th>
<th>Line</th>
<th>Identification of deposit</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>6</td>
<td>Name of depositary institution: CNCM Collection nationale de cultures de micro-organismes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Address of depositary institution: Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Date of deposit: 29 May 2009 (29.05.2009)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Accession Number: CNCM 1-4154</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Designated States for Which Indications are Made: all designations</td>
</tr>
</tbody>
</table>

FOR RECEIVING OFFICE USE ONLY

This form was received with the international application: YES

Authorized officer: Krista Delimon

FOR INTERNATIONAL BUREAU USE ONLY

This form was received by the international Bureau on:

Authorized officer:
Claims:

1. Oral nutritional supplement to be administered to children having a caloric density in the range of 0.9-1.6 kcal/ml, an osmolality in the range of 380-420 m\(\text{osm/kg water}, \) and comprising a protein source accounting for about 10-13% of the calories of the composition, a carbohydrate source accounting for about 43-55% of the calories of the composition, a lipid source accounting for about 33-46% of the calories of the composition and probiotic micro-organisms.

2. Oral nutritional supplement in accordance with claim 1 comprising a lipid source with a n6 : n3 fatty acid ratio in the range of 6:1 to 8:1, and/or an MCT : LCT ratio in the range of 12:88 to 8:92.

3. Oral nutritional supplement in accordance with one of the preceding claims, comprising about 70-73% free water.

4. Oral nutritional supplement in accordance with one of the preceding claims, wherein the protein source is selected from sodium and calcium caseinates from milk, whey protein concentrate or combinations thereof and has and NPC:N ratio in the range of 190:1 to 200:1.

5. Oral nutritional supplement in accordance with one of the preceding claims, wherein the probiotic micro-organisms comprise non-replicating probiotic micro-organisms.

6. Oral nutritional supplement in accordance with one of the preceding claims comprising probiotic micro-organisms in an amount corresponding to about \(10^6\) to \(10^{12}\) cfu.

7. Oral nutritional supplement in accordance with one of claims 5-6 wherein the non-replicating probiotic micro-organisms were rendered non-replicating by a heat-treatment, preferably by a high temperature treatment at at least 71.5 °C for at least 1 second.
8. Oral nutritional supplement in accordance with claim 7, wherein the heat treatment is a high temperature treatment at about 71.5-150 °C for about 1-120 seconds, and preferably is a high temperature/short time (HTST) treatment or a ultra-high temperature (UHT) treatment.

9. Oral nutritional supplement in accordance with claim 8 for use in the prevention or treatment of inflammatory disorders.

10. Oral nutritional supplement in accordance with claim 7, wherein the heat treatment is carried out in the temperature range of about 70-150 °C for about 3 minutes - 2 hours, preferably in the range of 80-140 °C from 5 minutes - 40 minutes.

11. Oral nutritional supplement in accordance with claim 10 for use in the prevention or treatment disorders related to a compromised immune defence.

12. Oral nutritional supplement in accordance with one of the preceding claims wherein at least 90 %, preferably, at least 95 %, more preferably at least 98 %, most preferably at least 99 %, ideally at least 99.9 %, most ideally all of the probiotics are non-replicating.

13. Oral nutritional supplement in accordance with one of the preceding claims wherein the probiotic microorganisms are selected from the group consisting of bifidobacteria, lactobacilli, propionibacteria, or combinations thereof, for example Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus easel, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus.
Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli and/or mixtures thereof.

14. Oral nutritional supplement in accordance with one of the preceding claims wherein the probiotic micro-organisms are selected from the group consisting of Bifidobacterium longum NCC 3001, Bifidobacterium longum NCC 2705, Bifidobacterium breve NCC 2950, Bifidobacterium lactis NCC 2818, Lactobacillus johnsonii La1, Lactobacillus paracasei NCC 2461, Lactobacillus rhamnosus NCC 4007, Lactobacillus reuteri DSM17983, Lactobacillus reuteri ATCC55730, Streptococcus thermophilus NCC 2019, Streptococcus thermophilus NCC 2059, Lactobacillus casei NCC 4006, Lactobacillus acidophilus NCC 3009, Lactobacillus casei ACA-DC 6002 (NCC 1825), Escherichia coli Nissle, Lactobacillus bulgaricus NCC 15, Lactococcus lactis NCC 2287, or combinations thereof.

15. Oral nutritional supplement in accordance with one of the preceding claims containing about 0.005 mg - 1000 mg non-replicating micro-organisms per daily dose.
Figure 4B
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, COMPENDEX, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>WO 2008/001086 A1 (SHS INTERNAT LTD [GB]; LANGFORD JANE ELIZABETH [GB]; SULLIVAN IAN [GB]) 3 January 2008 (2008-01-03) pages 3-5; claims 1-5,15</td>
<td>1-15</td>
</tr>
<tr>
<td>Y</td>
<td>WO 2004/069156 A2 (UNIV CALIFORNIA [US]; RAZ EYAL [US]; RACHMILEWITZ DANIEL [IL]) 19 August 2004 (2004-08-19) paragraphs [0042], [0047], [0053] - [0054], [0109], [0112]; claims 1,2,8,25</td>
<td>1-15</td>
</tr>
<tr>
<td>Y</td>
<td>WO 02/28402 A (NESTLE SA [CH]; BAUR MARKUS [DE]; BRETON LIONEL [FR]; COUZY FRANCOIS [FR]) 11 April 2002 (2002-04-11) pages 6-7; claims 1,2,8</td>
<td>1-15</td>
</tr>
</tbody>
</table>

Special categories of cited documents

*A* document defining the general state of the art which is not considered to be of particular relevance

*E* earlier document but published on or after the international filing date

*L* document which may throw doubts on novelty claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

*O* document referring to an oral disclosure, use, exhibition or other means

*P* document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"A" document member of the same patent family

Date of the actual completion of the international search: 17 September 2010

Date of mailing of the international search report: 27/09/2010

Authorized officer: Bochelen, Damien

Form PCT/ISA/210 (second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 2008001086 AI</td>
<td>03-01-2008</td>
<td>CN 101478891 A</td>
<td>08-07-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2034854 Al</td>
<td>18-03-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009238893 Al</td>
<td>24-09-2009</td>
</tr>
<tr>
<td>WO 2004069156 A2</td>
<td>19-08-2004</td>
<td>AU 2003303894 Al</td>
<td>30-08-2004</td>
</tr>
<tr>
<td>WO 0228402 A</td>
<td>11-04-2002</td>
<td>AR 033580 Al</td>
<td>26-12-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2058702 A</td>
<td>15-04-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2002220587 B2</td>
<td>29-06-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0114400 A</td>
<td>26-08-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2424607 Al</td>
<td>11-04-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1468105 A</td>
<td>14-01-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 4510376 B2</td>
<td>21-07-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004510740 T</td>
<td>08-04-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX PA03002957 A</td>
<td>30-06-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2004013706 Al</td>
<td>22-01-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010080782 Al</td>
<td>01-04-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2002247668 Al</td>
<td>12-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2002249151 Al</td>
<td>12-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2002302360 Al</td>
<td>03-10-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2435664 Al</td>
<td>26-09-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2436049 Al</td>
<td>08-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1518598 A</td>
<td>04-08-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1500146 A</td>
<td>26-05-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101671640 A</td>
<td>17-03-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 60215461 T2</td>
<td>03-05-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 1358332 T3</td>
<td>08-01-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0260931 A2</td>
<td>08-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0260932 A2</td>
<td>08-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 02074798 A2</td>
<td>26-09-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 22770819 T3</td>
<td>16-05-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 4249483 B2</td>
<td>02-04-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004531229 T</td>
<td>14-10-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004531245 T</td>
<td>14-10-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 1358332 E</td>
<td>31-01-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2004115773 Al</td>
<td>17-06-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2004126870 Al</td>
<td>01-07-2004</td>
</tr>
</tbody>
</table>